CUTIA-B(02487): The market authorization application for CU-20101 (Botulinum Toxin Type A for Injection) biological product has been accepted by the National Medical Products Administration.

CUTIA-B (02487) announced that the biological product license application (BLA) for the groups CU-20101 (injectable type A botulinum toxin) has been accepted by the National Medical Products Administration of China, with the indication for improving moderate to severe glabellar lines. CU-20101 will not use animal-derived materials and human serum albumin during the production process, thereby eliminating the risk of transmissible spongiform encephalopathy (TSE) infection and related allergic reactions, and is expected to have a strong safety advantage. CU-20101 will further enrich the groups skincare product matrix and facilitate synergy with the groups existing products. Given the widespread demand in the skincare treatment market, a diversified product portfolio is expected to help the group gain a larger market share.